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Aim: This study aims to determine the incidence of all immune-mediated adverse events (IMAEs) with
a focus on hypophysitis in patients with metastatic melanoma receiving immune checkpoint inhibitors
(ICI). Methods: 51 patients with metastatic melanoma who received immune checkpoint inhibitors (ipil-
imumab, pembrolizumab and nivolumab) in Ninewells Hospital, Dundee between 2014 and 2018 were
identified. Patient demographic data and outcomes were recorded retrospectively. Results: A total of 6
patients (11.7%) developed hypophysitis, while 15 patients (29.4%) developed IMAEs. A significant im-
provement in overall survival (p = 0.03) and progression-free survival (p = 0.041) was seen in patients who
developed IMAEs compared with those who did not. Conclusion: This study demonstrates a high rate of
hypophysitis in melanoma patients receiving ipilimumab. Careful monitoring of symptoms is crucial to
detect and appropriately manage IMAEs.
First draft submitted: 25 November 2018; Accepted for publication: 19 March 2019; Published online:
18 April 2019
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To prevent recognition and destruction by cytotoxic T cells, cancer cells express ligands that activate T-cell inhibitory
receptors, which downregulate their function [1,2]. Antibodies, which target these ligands and expose cancer cells
to T-cell recognition, are known as immune checkpoint inhibitors (ICIs) and these agents are now the cornerstone
of treatment for metastatic melanoma [3,4]. Among the immune inhibitory pathways that have been identified, the
CTLA-4 and PD-1 pathways have demonstrated significant promise in the clinical setting.
Anti-CTLA-4 antibodies such as ipilimumab and anti-PD-1 antibodies such as pembrolizumab and nivolumab
have been approved by the ScottishMedicine Consortium for the treatment of metastatic melanoma since 2014 [5,6].
An ever-growing evidence base demonstrates improved survival and patient outcomes with immunotherapy com-
pared with traditional chemotherapy [7,8]. The majority of adverse events associated with ICIs are mild in nature;
however, a proportion of patients do experience grade 3 and 4 toxicities [9–11]. Rarely, potentially fatal immune-
mediated adverse events (IMAEs) such as immune hypophysitis have been observed in patients receiving ICIs [12,13].
Hypophysitis is the inflammation of the pituitary gland, which often leads to irreversible hypopituitarism and
can potentially lead to adrenal crisis if left untreated [14,15]. Clinical trial data have suggested rates of hypophysitis
up to 17% in patients receiving ipilimumab [16,17]. In comparison, anti-PD1 inhibitors such as pembrolizumab and
nivolumab have demonstrated lower rates of hypophysitis – 0.47% based on a meta-analysis of nine randomized
trials [18].
The reason underlying high rates of ipilimumab-mediated hypophysitis is thought to relate to expression of
CTLA-4 in the pituitary. Experimental murine studies have demonstrated the expression of CTLA-4 coding
RNA and elevated protein levels in pituitary cells. Analysis of a cohort of 20 patients demonstrated that pituitary
antibodies, negative at baseline, developed in the seven patients with hypophysitis but not in the 13 patients without,
suggesting a potential mechanism for immune-mediated hypophysitis through the development of anti-CTLA4
antibodies causing hypophysitis [19].
In our center, we have noticed a disproportionate increase in the incidence of hypophysitis in our cohort since
the inception of these immunotherapeutic agents. Therefore, this study aims to investigate the incidence of all
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IMAEs with a focus on hypophysitis for patients with metastatic melanoma who received an ICI (ipilimumab,
nivolumab and pembrolizumab) in Ninewells Hospital, Dundee, and to compare with published literature.
Methods
All patients with metastatic melanoma who received an ICI (ipilimumab, nivolumab and pembrolizumab) between
January 2014 and August 2018 at our center (Ninewells Hospital, Dundee, Scotland) were identified from
electronic chemotherapy records. Baseline patient demographic data were collected including age, sex, date of
diagnosis, performance status on commencing treatment and treatment received.
In our center, we have two generic databases that store patient’smedical notes and correspondence (Clinical Portal)
as well as Laboratory investigations Integrated Clinical Environment (ICE). Furthermore, the database (Wisdom)
contains all day to day progress for patients when they attend radiotherapy, chemotherapy or immunotherapy
sessions. The practice nurse/doctor will document the procedure undertaken as well as monitor for any adverse
reactions that the patient might have suffered from. The second database (Chemocare) records specifically the type,
date and time of administration of immunotherapy, use of adjunct medication as well as any further reports of
adverse reaction or ill health.
All four of these databases have been studied and every incidence of possible IMAEs including hypophysitis that
had been reported and documented in these records has been included in this study. If present, management and
outcome were recorded.
All patients who received ICIs at our center have had a toxicity assessment prior to every cycle, where baseline
bloods inclusive of full blood count, urea and electrolytes, liver function test, bone profile, cortisol and thyroid
function test were tested. Where there was a clinical indication, a more comprehensive hormone panel was carried
out.
In this study, the diagnosis of hypophysitis was made based on the correlation of patient symptoms with the
timing of administration of immunotherapy, as well as biochemical and radiological evidence demonstrating the
development of hypopituitarism. A thyrotroph deficiency was defined as a low plasma T4 level (<9.8 pmol/l)
with low or inappropriately normal levels of thyroid-stimulating hormone. Corticotroph deficiency was defined
as low cortisol levels (<275 nmol/l) with low or inappropriately normal levels of adrenocorticotropic hormone.
Gonadotroph deficiency was defined as low sex steroids (testosterone/estradiol) with inappropriately normal levels
of follicle-stimulating hormone and luteinizing hormone levels. Last, lactotroph deficiency is defined as low levels
of prolactin (<6 mU/l). Levels of growth hormone and IGF-1 were also recorded.
Recovery from hypophysitis was defined as a normalization of hormone profile as evidenced by blood tests as
well as clinical recovery. Clinical recovery was defined as the patient no longer requiring hormone replacement
therapy at the end of the follow-up period.
After collection of data, the study population was stratified into two groups according to treatment type and
presence of IMAEs. Progression-free survival was defined as the time from commencing treatment to radiological
evidence of progression. Overall survival was defined as the date from treatment commencement to date of death or
end of the follow-up period. Grading of adverse events is based on the Common Terminology Criteria for Adverse
Events version 5.0 [20].
All data were analyzed using SPSS (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.).
Outcome data from this study were compared using Log-rank analysis to evaluate overall and progression-free
survivals between both groups (where p < 0.05 is considered to be statistically significant). Local ethical approval
was obtained prior to collection of data.
Results
Patient demographics
A total of 51 patients were identified as having received an ICI during the time period specified and were included
in this study. Table 1 summarizes the characteristics of the study population. The majority of patients were male
(74.5%), had a performance status of 0–1 (96%) and had a wild-type BRAF status (70.6%). Additionally, 84.3%
of our patients have received surgical excision of their primary cutaneous melanoma previously prior to a relapse of
their disease, which necessitate the use of immunotherapy. Most patients received no previous systemic treatments
(86.3%). Out of the seven patients who received previous systemic treatments, three had received ipilimumab
immunotherapy previously, while the remaining four received conventional chemotherapy. To note, it is this
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Table 1. Summary of patient demographics.
Demographic Number
Age, median (months) 67 ± 14.3
Duration of follow-up, median (months) 7 (1–55)
Gender: Male 38 (74.5%)
Female 13 (25.5%)
Performance status: 0 30 (58.8%)
1 19 (37.2%)
2 2 (4.0%)
Cancer type: Cutaneous melanoma 46 (90.2%)
Ocular melanoma 5 (9.8%)
Primary cancer resected prior to therapy: Yes 43 (84.3%)
No 8 (15.7%)
Number of systemic treatments prior to therapy: 0 44 (86.3%)
1 7 (13.7%)
BRAF mutation status: Wild-type 36 (70.6%)
Positive 6 (11.8%)
Unknown 9 (17.6%)
Nature of prior treatment: Immunotherapy 3
Chemotherapy 4
Type of immunotherapy: Ipilimumab 16 (31.4%)
Nivolumab 2 (3.9%)
Pembrolizumab 33 (64.7%)
Mean number of cycles of immunotherapy: Ipilimumab 3.5 (2–4)
Nivolumab 3.5 (3–4)
Pembrolizumab 14.7 (1–50)
Presence of hypophysitis: Yes 6 (11.7%)
No 45 (88.3%)
center’s policy to utilize immunotherapy as first line to treat metastatic melanoma, while BRAF inhibitors such as
dabrafenib are used second line where BRAF mutation is positive.
All patients received their care in Ninewells Cancer Center, Dundee, from initiation of treatment until either
the end point of the study or death, median follow-up was 7 months, ranging from 1 to 55 months. Two patients
emigrated from the country for end of life care and were lost to follow-up.
Hypophysitis characteristics & management
A total of six patients (11.7%) developed clinically significant hypophysitis during their treatment (Table 2). Five
of these patients had received ipilimumab (incidence of 31.3% in those who received ipilimumab) and one had
received pembrolizumab (incidence of 3.0% in those receiving pembrolizumab). Table 2 shows the presenting
features of each patient with hypophysitis.
Out of the six cases of hypophysitis, four patients required hospitalization, one patient (grade 2) was diagnosed
and treated medically as an outpatient, while one patient had grade 1 hypophysitis and was completely asymp-
tomatic (Patient 5). He was only diagnosed as routine blood monitoring has demonstrated mild corticotropin and
thyrotropin deficiency.
The patients who developed hypophysitis presented with nonspecific symptoms such as headache, nausea and
vomiting. Two patients developed other IMAEs, both of which had a grade 1 rash. Four out of six (66.7%) patients
were treated with systemic steroid therapy (Dexamethasone) and steroid treatment duration ranged from 7 to 39
days. Treatment dose of dexamethasone was tailored according to the clinical picture. The remaining two patients
were not treated with dexamethasone as one of them was asymptomatic with only mild hormonal deficiencies
(Patient 5), while the other (Patient 6) was started on intravenous hydrocortisone upon admission as per advice
from the endocrinology team.
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Table 2. Cases of immunotherapy-induced hypophysitis.
Case number 1 2 3 4 5 6
Age 70 70 64 77 46 24
Gender (M/F) M F M M M F
Immunotherapy Ipilimumab Ipilimumab Ipilimumab Ipilimumab Ipilimumab Pembrolizumab
Treatment dose
(mg/kg)
3 3 3 3 3 2
Number of cycles
prior to event
3 4 4 2 3 35
Hormonal defect
(time of diagnosis)
Corticotroph,
thyrotroph,
gonadotroph
Corticotroph,
thyrotroph
Corticotroph,
gonadotroph
Corticotroph,
thyrotroph,
gonadotroph
Corticotroph,
thyrotroph
Corticotroph, primary
hypothyroidism
MRI findings No abnormalities No abnormalities Not performed No abnormalities Not performed Not performed
Symptoms Headache, syncope Nausea Tiredness Headache Asymptomatic Nausea, vomiting
Dexamethasone dose
(mg)
16 8 8 10 Not given Not given
Recovery from event No No Yes No Yes No
Hormone
replacement (at the
end of follow-up)
Levothyroxine,
testosterone,
hydrocortisone
Hydrocortisone,
levothyroxine
None Hydrocortisone,
levothyroxine
None Hydrocortisone,
levothyroxine
Additional IMAEs None Rash None Rash None None
F: Female; IMAE: Immune mediated adverse event; M: Male; MRI: Magnetic resonance imaging.
Table 3. Immune-mediated adverse events.
Case Immunotherapy Immune-mediated adverse effect Grade
1 Pembrolizumab Dermatitis in lips 1
2 Pembrolizumab Rash 1
3 Pembrolizumab Rash 1
4 Pembrolizumab Hypothyroidism 1
5 Pembrolizumab Hypothyroidism 2
6 Pembrolizumab Hypothyroidism 2
7 Pembrolizumab Thrombocytopenia 3
8 Pembrolizumab Hypophysitis 3
9 Ipilimumab Hypophysitis 1
10 Ipilimumab Rash 1
11 Ipilimumab Colitis 2
12 Ipilimumab Hypophysitis 2
13 Ipilimumab Hypophysitis 3
14 Ipilimumab Hypophysitis 3
15 Ipilimumab Hypophysitis 3
All patients demonstrated corticotroph deficiency, four patients required lifelong hydrocortisone replacement
while two patients recovered from their hypopituitarism at the end of the follow-up period. Thyroid function
derangement was observed in five patients. Four patients demonstrated biochemical evidence of secondary hy-
pothyroidism; however, one patient had concurrent primary hypothyroidism and hypophysitis. Four patients
required lifelong levothyroxine replacement, while the remaining patients recovered. Gonadotrophic deficiency was
observed in three patients on diagnosis; however, two patients recovered while one patient required testosterone
replacement at the end of follow-up. MRI was performed shortly (within 1 week) after presentation in three
patients, all of which demonstrated unremarkable findings.
Including the six patients who developed hypophysitis, a further nine (18%) patients (Table 3) developed
IMAEs, most of which were grade 1–2; three developed primary hypothyroidism, with two requiring levothyroxine
replacement. There were six cutaneous reactions (rash and dermatitis) and one incident of grade 3 immune-mediated
thrombocytopenia and colitis each.
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Figure 1. Kaplan–Meier survival curve comparing overall survival of patients who received ipilimumab versus those
who received pembrolizumab (p = 0.180).
Table 4. Characteristics of patients treated with ipilimumab versus pembrolizumab.
Patient Characteristics Ipilimumab (n = 16) Pembrolizumab (n = 33) p-value
Age 62.63 64.33 0.691
Gender (% male) 68.75% 75.76% 0.624
Overall survival (median) 18.3 months;
95% CI: 9.2–27.4
21.6 months;
95% CI: 16.4–26.7
0.180
Progression-free survival (median) 12.1 months;
95% CI: 2.9–21.24
19.8 months;
95% CI: 13.9–25.7
0.042
Patient outcome data
There was no statistically significant difference in overall survival (Figure 1; 21.6 vs 18.3months; p = 0.180) between
patients who received pembrolizumab and those who received ipilimumab (Table 4). However, pembrolizumab
provides a better progression-free survival for patients as compared with ipilimumab (Figure 2; 19.8 vs 12.1 months;
p = 0.042).
Log-rank (Mantel Cox) analysis (Figures 3 & 4) demonstrated a significant difference in overall survival (20.6
vs 11.1 months, p = 0.030) and progression-free survival (16.7 vs 6.38 months; p = 0.041) among patients who
develop IMAEs (Table 5). There is no observable difference in age or gender distribution seen in both groups.
At the end point of follow-up, only two patients (33.33%) recovered their pituitary function and did not require
lifelong hormone replacement.
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Figure 2. Kaplan–Meier survival curve comparing progression-free survival of patients who received ipilimumab
versus those who received pembrolizumab (p = 0.042).
Table 5. Characteristics of patients with and without immune-mediated adverse event.
Patient characteristics Affected (n = 15) Not affected (n = 36) p-value
Age 64.5 63.6 0.846
Gender 73.3% 75.0% 0.906
Overall survival (median) 20.6 months;
95% CI: 10.9–30.3
11.1 months;
95% CI: 7.8–14.5
0.030
Progression-free survival (median) 16.7 months;
95% CI: 6.9–26.6
6.38 months;
95% CI: 3.7–9.1
0.041
Discussion
ICIs have revolutionized the treatment of metastatic melanoma. With growing experience and ongoing studies
evaluating the efficacy and safety of agents such as ipilimumab and pembrolizumab, the initiation of such treatments
can be confidently made. Increasing awareness of the potential side effects has also led to the development of adverse
event treatment guidelines [21,22]. This study aimed to quantify objectively the adverse event profile of these agents
in the melanoma patient population in the east of Scotland.
The use of ipilimumab to treat melanoma has been discontinued in this cancer center from 2015 due to
growing concerns of its toxicity and with the introduction of newer and safer agents such as pembrolizumab and
nivolumab. Combination treatment of ipilimumab and nivolumab is also avoided due to toxicity. This study has
demonstrated that anti-PD1 inhibitors provide superior patient outcomes in terms of progression-free survival
and safety. Multiple Phase III clinical trials have demonstrated improved overall and progression-free survivals for
pembrolizumab compared with ipilimumab [23–26].
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Figure 3. Kaplan–Meier survival curve comparing overall survival of patients affected by immune-mediated adverse
reaction versus those who did not (p = 0.030).
In this population, patients taking pembrolizumab developed a lower rate of IMAEs compared with those
taking ipilimumab. Moreover, these adverse reactions are often mild and self-limiting, with most patients having
only grade 1 and 2 toxicity. This is in contrast to ipilimumab where 42.9% of patients suffered from grade 3
IMAE in contrast to 25% in the pembrolizumab cohort. Three patients (9%) developed hypothyroidism in the
pembrolizumab cohort, consistent with the findings of a large systematic review, which found that hypothyroidism
is the most common endocrine disorder seen, at a rate of 8% [27].
All six patients who developed hypophysitis demonstrated a variety of hormonal deficiencies, albeit of varying
severity. For example, one patient was asymptomatic andmade a complete recovery of his pituitary function without
need for systemic steroid treatment or hormone replacement. In contrast, four patients required hospitalization,
high-dose dexamethasone or intravenous hydrocortisone replacement to effectively manage their symptoms. Ul-
timately, the majority of these patients required long-term hormone replacement. This observation is consistent
with the often unpredictable natural history and severity of hypophysitis that has been described in the current
literature [28,29]. This further elucidates the necessity of tailoring the treatment according to the individual patient,
with appropriate monitoring to help determine whether to continue with the immunotherapy regime or to switch
to other conventional therapies [30,31].
Another interesting finding in this study is the lack of radiological findings in the patient cohort; three out of
six patients (50%) who developed hypophysitis received a brain MRI, which failed to demonstrate any significant
abnormalities. This is in contrast to the typical findings of an enlarged pituitary gland or infundibulum that is
commonly described in other studies investigating this [32–34]. However, while MRI imaging can aid in reaching
the diagnosis, it lacks in specificity particularly when distinguishing hypophysitis and pituitary adenomas or
incidentalomas. As such, careful correlation with clinical history and biochemical findings is still necessary [14].
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Figure 4. Kaplan–Meier curve comparing progression-free survival of patients affected by immune-mediated
adverse reaction versus those who did not (p = 0.041).
Furthermore, this study population has a lower percentage of BRAF mutant melanoma (11.8%) compared with
what has been reported in the literature, where a rate of approximately 50% is expected [35]. This finding may
represent the variation in the local population leading to a mismatch with other trails population or could be
coincidental due to the study’s small sample size.
With a small sample size (n = 51), it is difficult to draw inferences on the prevalence of hypophysitis from
this cohort. However, the study data seem to suggest higher rates of hypophysitis both among patients taking
ipilimumab and pembrolizumab. The current literature suggests an incidence of 0–17% for hypophysitis among
the ipilimumab patient cohort [17]. To note, while a hypophysitis rate of 0.47% has been quoted in the meta-analysis
performed by Costa et al. assessing the toxicity profile of pembrolizumab and nivolumab in solid tumors, Wang et
al. have demonstrated in their study that pembrolizumab causes a hypophysitis rate of <0.01% specifically in the
metastatic melanoma patient cohort [18,27]. To compare, this study’s cohort demonstrates a rate of 31.3 and 3.0%
for ipilimumab and pembrolizumab, respectively.
A possible explanation of the higher rates seen is that there has been an increased vigilance in monitoring patients
for IMAEs and a lower threshold to investigate patients presenting with nonspecific symptoms in recent years.
Indeed, many earlier studies have attributed a possibility of under-reporting IMAEs due to poor recognition [36,37].
The overall incidence for all grade IMAEs for this cohort is 43.8 and 27.3% for ipilimumab and pembrolizumab,
respectively. To compare, two meta-analysis analyzing the adverse effect profile of these two immunotherapy agents
reported an incidence of 61 and 26.8% for ipilimumab and pembrolizumab, respectively [17,27]. Our study data
broadly match the incidence of reported IMAEs in clinical trials – although we do recognize that our rates for
ipilimumab are lower. This observation is likely associated to a smaller ipilimumab patient cohort due to the shorter
duration of use of this agent in our center before it was discontinued, allowing less IMAEs to be recorded.
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At the time of treatment, ipilimumab and pembrolizumabwere prescribed at a dose of 3 and 2mg/kg, respectively.
We are aware that flat dosing is now standard of care and this is under review at our center. However, this study
was not able to elicit a demonstrable difference in cumulative dose between patients who develop hypophysitis and
those who did not, as has been shown in other studies [17,27,35]. This is perhaps again attributed to the small sample
size.
Interestingly, the data from this study demonstrated statistically and clinically significant improvement in overall
and progression-free survivals for patients taking ICIs who develop IMAEs. Though the exact mechanism for this
is unknown, multiple studies conducted have also similarly reported improved tumor response rate and increased
survival rates with patient who develop IMAEs [38–40].
Conclusion
This study demonstrates that the incidence of IMAEs and, in particular, hypophysitis in this center’s population
is higher in patients on ipilimumab compared with pembrolizumab. There is an observable increase in incidence
of hypophysitis in this cohort as compared with the general study population. The data also support emerging
evidence that suggests better overall and progression-free survivals in patients who develop immune-mediated
adverse reactions compared with those who did not. With the increased use on ICIs, medical professionals need
to be aware of the potential serious adverse events and need to become better at recognizing and managing these
specific toxicities.
Future perspective
From this author’s perspective, there aremany new emerging immunotherapies that are currently being trialled at dif-
ferent phases. New immunotherapies and new combinations of immunotherapies/targeted therapy/chemotherapy
are now being actively investigated; these will provide clinicians with far more options for treatment as compared
with what we currently have now. However, as these treatments are introduced into clinical practice, great care
has to be taken to avoid increasing morbidity and mortality in the pursuit of a cure. With the introduction of
new treatment regimens and agents, new protocols for monitoring and guidance for managing associated adverse
events will be needed to ensure that patients obtain maximal benefit from these treatments. Another area of great
improvement that can be anticipated is the development of biomarkers, which will allow us to personalize treatment
for our patients where laboratory tests will help us select patients who will respond to certain treatment or help us
exclude patients who might develop severe adverse reactions.
Summary points
• Immune checkpoint inhibitors are effective in treating metastatic melanoma, but are known to cause
immune-mediated adverse events (IMAEs), which can result in lifelong endocrine complications.
• Out of 51 patients with metastatic melanoma treated with immune checkpoint inhibitors in Ninewells Hospital,
Dundee, a total of 6 patients (11.7%) developed clinically significant hypophysitis, 5 patients had received
ipilimumab and 1 had received pembrolizumab.
• A further nine patients developed other IMAEs; three developed primary hypothyroidism, with a further six
cutaneous reactions and one incident of immune-mediated thrombocytopenia and colitis each.
• There is a greater rate of the development of hypophysitis in our center than reported in published literature.
• A significant difference in overall survival (20.6 vs 11.1 months, p = 0.03) and progression-free survival (16.7 vs 6.4
months, p = 0.041) was observed among patients who develop IMAEs compared with those who did not.
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